Abstract:Abstract Glioma is the most frequent tumor in central nervous system (CNS), which makes up about 30% of CNS tumors. The current standard strategy for glioma treatment is surgery plus adjuvant chemotherapy and concurrent radiotherapy. Even though, the prognosis of glioma is still poor. It’s encouraging that temozolomide (TMZ) prolongs the overall survival of glioma patients, but the following TMZ resistance is really frustrating. It’s urgent to figure out efficient ways to improve the long term prognosis of patients, such as antagonizing the TMZ resistance. Ferroptosis was a newly discovered type of regulated cell death characterized by iron-dependent aberrant lipid peroxidation and membrane damage in the last decade. Ferroptosis-associated iron transport proteins modulate the process precisely through controlling the iron content. ZIP14, also known as SLC39A14, is an eight-transmembrane protein which could transport divalent metal ion like Mn2+, Zn2+ and Fe2+. Our preliminary data showed that the expression level of ZIP14 was higher in tumor tissues than paired normal tissue, which was corelated with poor prognosis of glioma. Knock down ZIP14 could induce cell death, and which could be rescued by inhibitors for ferroptosis but not for apoptosis or necrosis. Knock down ZIP14 decreased the ferroptosis inhibition by Ferroptosis suppress protein 1 (FSP1) which through reduction of lipid peroxidation, and sensitized cells to TMZ. Furthermore, we found that ZIP14 formed a complex with Ubiquinone. And it was known that FSP1 is critical in the switch of ubiquinone to ubiquinol. Therefore, we propose that ZIP14 suppress lipid peroxidation through blockage of the transition of ubiquinone to ubiquinol. While ZIP14 was knocked down, the complex with Ubiquinone wad damaged, and could not further change to Ubiquinol, so the suppression to lipid peroxidation was released, and then, ferroptosis was upregulated. In this study, we are going to figure out the molecular mechanism about how ZIP14 suppress ferroptosis and find out efficient small molecule inhibitors to activate ferroptosis by abolishing ZIP14 and improve the prognosis of glioma patients. Citation Format: Jing Wang. Targeting the suppressor of ferroptosis to improve the treament effeciency of glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 361.

Supplementary Figure S2 from the DRD2 Antagonist Haloperidol Mediates Autophagy-Induced Ferroptosis to Increase Temozolomide Sensitivity by Promoting Endoplasmic Reticulum Stress in Glioblastoma

A targetable PRR11-DHODH axis drives ferroptosis- and temozolomide-resistance in glioblastoma

Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists

Temozolomide Drives Ferroptosis via a DMT1-Dependent Pathway in Glioblastoma Cells

Abnormally Expressed Ferroptosis-Associated FANCD2 in Mediating the Temozolomide Resistance and Immune Response in Glioblastoma

Biochemical evidence for cholinergic activity in retinal blood vessels.

NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation

Research on “Big Ticket” Items: Ethical Implications for Equitable Access

HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis

Autophagy-dependent ferroptosis as a potential treatment for glioblastoma

ALDH1-Mediated Autophagy Sensitizes Glioblastoma Cells to Ferroptosis

The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis

High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1/MRP1 upregulation

Figure S4 from HERC3-Mediated SMAD7 Ubiquitination Degradation Promotes Autophagy-Induced EMT and Chemoresistance in Glioblastoma

Abstract 361: Targeting the suppressor of ferroptosis to improve the treament effeciency of glioblastoma

Disulfiram, a Ferroptosis Inducer, Triggers Lysosomal Membrane Permeabilization by Up-Regulating ROS in Glioblastoma

Postoperative Injection of a Triptolide‐Preloaded Hydrogel Prevents the Recurrence of Glioblastoma by Dual‐Pathway Activation of Ferroptosis

Electron-Accepting Micelles Deplete Reduced Nicotinamide Adenine Dinucleotide Phosphate and Impair Two Antioxidant Cascades for Ferroptosis-Induced Tumor Eradication

Reversing ferroptosis resistance by MOFs through regulation intracellular redox homeostasis

Acidity-Biodegradable Iridium-Coordinated Nanosheets for Amplified Ferroptotic Cell Death Through Multiple Regulatory Pathways

Proteogenomic characterization of ferroptosis regulators reveals therapeutic potential in glioblastoma